<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Insulin infusion</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Vicentra raises $85M for Kaleido insulin patch pump</title>
      <description>
        <![CDATA[Vicentra BV’s insulin patch pump, Kaleido, will soon reach more patients with diabetes after it raised $85 million in a series D funding round. The company said the Kaleido is among the smallest, lightest, and most precise insulin patch pumps available.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723561</guid>
      <pubDate>Wed, 03 Sep 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723561-vicentra-raises-85m-for-kaleido-insulin-patch-pump</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/User-with-Kaleido-3sept25.webp?t=1756934843" type="image/jpeg" medium="image" fileSize="441344">
        <media:title type="plain">User with Kaleido</media:title>
        <media:description type="plain">User with Kaleido. Credit: Vicentra</media:description>
      </media:content>
    </item>
    <item>
      <title>Top Med-tech Trends of 2021: Diabetes market poised for growth, despite pandemic</title>
      <description>
        <![CDATA[Diabetes care will continue to evolve in 2022. New digital offerings and advanced algorithms, along with new product launches in insulin pumps and continuous glucose monitoring (CGM) will power growth in the future, according to key analysts. While many medical device sectors have suffered during the COVID-19 pandemic, diabetes care has continued to grow.]]>
      </description>
      <guid>http://www.bioworld.com/articles/514405</guid>
      <pubDate>Mon, 20 Dec 2021 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/514405-top-med-tech-trends-of-2021-diabetes-market-poised-for-growth-despite-pandemic</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Diabetes/diabetes-management.webp?t=1593552366" type="image/png" medium="image" fileSize="190736">
        <media:title type="plain">doctor, checklist, apple, prescription bottle and blood glucose meter illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Insulet’s Omnipod insulin delivery system hits its mark in pivotal diabetes trial</title>
      <description>
        <![CDATA[Insulet Corp. reported positive results from a pivotal trial of its Omnipod 5 automated insulin delivery system for patients with type 1 diabetes. The tubeless, wearable insulin delivery system lowered hemoglobin A1c (HbA1c) &ndash; a critical diabetes measure &ndash; in children, adolescents, and adults, and improved the time that patients were in the target blood glucose range. The data was presented at ENDO 2021, the Endocrine Society&rsquo;s annual meeting, which was held virtually this year.]]>
      </description>
      <guid>http://www.bioworld.com/articles/505097</guid>
      <pubDate>Tue, 23 Mar 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/505097-insulets-omnipod-insulin-delivery-system-hits-its-mark-in-pivotal-diabetes-trial</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/03-23-Insulet-Omnipod5.webp?t=1616537121" type="image/png" medium="image" fileSize="167361">
        <media:title type="plain">Product image</media:title>
        <media:description type="plain">The Omnipod 5 automated insulin delivery system. Credit: Insulet Corp.</media:description>
      </media:content>
    </item>
    <item>
      <title>Vicentra overcomes supply issues, regroups to raise €10M</title>
      <description>
        <![CDATA[LONDON – Vicentra BV has bounced back from COVID-19 related disruptions of its supply chain to raise a €10 million (US$11.44 million) round that will enable the company to reshape manufacturing and get its wireless insulin pump back on the market later in the year.]]>
      </description>
      <guid>http://www.bioworld.com/articles/471743</guid>
      <pubDate>Mon, 20 Jul 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/471743-vicentra-overcomes-supply-issues-regroups-to-raise-10m</link>
    </item>
    <item>
      <title>Insulet to launch wearable insulin pump this year, works with Dexcom iCGM for closed loop</title>
      <description>
        <![CDATA[SAN FRANCISCO &ndash; Insulet Corp. aims to get an FDA approval this year and launch its first interoperable device, the cord-free, wearable insulin device Omnipod Horizon. It is designed to be compatible with the Dexcom G6 and is the result of a partnership between the two companies. In combination, the devices will operate as a closed loop system to automatically adjust insulin dosage over time in response to blood glucose levels.]]>
      </description>
      <guid>http://www.bioworld.com/articles/432427</guid>
      <pubDate>Wed, 15 Jan 2020 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/432427-insulet-to-launch-wearable-insulin-pump-this-year-works-with-dexcom-icgm-for-closed-loop</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/1-15-insulet-omnipod-dash.webp?t=1579125344" type="image/png" medium="image" fileSize="1192391">
        <media:title type="plain">1-15-insulet-omnipod-dash.png</media:title>
        <media:description type="plain">Omnipod Dash system. Credit: Insulet Corp.</media:description>
      </media:content>
    </item>
    <item>
      <title>Tandem raises 2019 guidance on strength of its Q3 results</title>
      <description>
        <![CDATA[San Diego-based <a href="https://www.cortellis.com/intelligence/qsearch/&quot;Tandem Diabetes Care&quot;" target="_blank">Tandem Diabetes Care Inc</a>. reported financial results for the third quarter of 2019, with worldwide pump shipments soaring 112% to 17,839 pumps from 8,434 pumps in the same period a year ago. Revenue rose 105% to $94.7 million, up from $46.3 million in the third quarter of 2018.]]>
      </description>
      <guid>http://www.bioworld.com/articles/430985</guid>
      <pubDate>Wed, 06 Nov 2019 00:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/430985-tandem-raises-2019-guidance-on-strength-of-its-q3-results</link>
    </item>
  </channel>
</rss>
